About Endofotonics
Endofotonics is a company based in Singapore (Singapore) founded in 2014 by Cheng Tim Kum and Huang Zhi Wei. Endofotonics has raised $8.5 million across 2 funding rounds from investors including ZIG Ventures and Seeds Capital. Endofotonics operates in a competitive market with competitors including SamanTree Medical, Scholar Rock, Lightpoint Medical, Ionpath and Metrohm, among others.
- Headquarter Singapore, Singapore
- Founders Cheng Tim Kum, Huang Zhi Wei
- SectorsHealthcareTechnology
- Email••••••••
- Website endofotonics.com
- Social LinkedIn
- Legal Name Endofotonics Pte Ltd
- Net Profit-$1.37 M (USD)-28as on Jun 30, 2021
- EBITDA-$964.67 K (USD)-59as on Dec 31, 2019
- Total Equity Funding$8.5M (USD)
in 2 rounds
- Latest Funding Round$8.5M (USD), Series B
May 2020
- InvestorsZIG Ventures
& 1 more
Funding Insights of Endofotonics
Endofotonics has successfully raised a total of $8.5M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $8.5 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.5M
- Total Rounds 2
- Last Round Series B — $8.5M
- Investors Count 2
All 2 funding rounds of Endofotonics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $8.5M | Series B | – | – | – |
| Jun 2016 | – | Series A | – | ZIG Ventures, Seeds Capital | – |
2 investors in total: 2 institutional.
Investors in Endofotonics
Endofotonics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include ZIG Ventures and Seeds Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
ZIG Ventures is focused on healthcare innovation investments. | 2019 | ziggroup.com.sg | Singapore, Singapore | |
Nanotechnology-based battery solutions are provided via an online platform. | – | seedscapital.com | Sedgefield, United Kingdom |
Investor details for Endofotonics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Endofotonics
12 people are tracked at Endofotonics (5 in leadership, 6 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Cheng Tim Kum | Co-Founder | Leadership |
Huang Zhi Wei | Co-Founder | Leadership |
Chew Jing Ming | COO | Leadership |
Peter Cheng | CEO | Leadership |
Lawrence Ho Khek Yu | Chief Medical Officer & Co-Founder | Leadership |
Tony Tan Choon Keat | Director | Board & advisors |
Lui Pao Chuen | Director | Board & advisors |
Sim Giok Lak | Chairman | Board & advisors |
Sim Kok Hwee | Director | Board & advisors |
Beng Teck Liang | Director | Board & advisors |
Jen Kwong Hwa | Director | Board & advisors |
Hui Ying Leong | Finance Manager | Team |
Complete people profiles for Endofotonics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Endofotonics
3 dated milestones of Endofotonics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Endofotonics is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $8.5M.
Competitors of Endofotonics
Endofotonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SamanTree Medical, Scholar Rock, Lightpoint Medical, Ionpath and Metrohm, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| samantree.com | 2014 | Lausanne, Switzerland | $33.78M | – | A surgical digital microscope for tumor resection is developed. | |
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. | |
| lightpointmedical.com | 2012 | Rickmansworth, United Kingdom | $25.33M | 19 | Intraoperative imaging devices for real-time cancer detection are developed. | |
| ionpath.com | 2014 | Menlo Park, United States | $18M | 37 | Multiplexed ion beam imaging platform for tissue biopsies is developed. | |
| metrohm.com | 1943 | Herisau, Switzerland | – | 608 | Instruments for chemical analysis are developed and manufactured. | |
| fluxionbio.com | 2005 | San Francisco, United States | $20.85M | – | Microfluidics-based tools for cellular analysis are provided. | |
| impedimed.com | 1999 | Carlsbad, United States | $3.44M | 76 | Technologies for non-invasive fluid status assessment and monitoring are developed. | |
| phasefocus.com | 2006 | Sheffield, United Kingdom | $12.08M | 10 | Provider of virtual lens that generates High definition images without high-quality lenses | |
| perfinthealthcare.com | 2005 | Chennai, India | $41.48M | 36 | Solutions for image-guided interventional procedures are developed. | |
| speclipse.com | 2015 | Seongnam-si, South Korea | $10.55M | – | Molecular spectroscopy systems for early skin cancer detection are provided. |
Detailed competitors of Endofotonics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Endofotonics
Complete news archive for Endofotonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Endofotonics
10 companies that operate in the same segment as Endofotonics (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Endofotonics
Endofotonics was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Endofotonics is headquartered in Singapore, Singapore.
Peter Cheng is the current CEO of Endofotonics.
Endofotonics is a funded company, having raised a total of $8.5M across 2 funding rounds to date.
Endophotonics is a medical device company that has developed an endoscopic system based on Raman Spectroscopy. The IMDX system consists of a Raman Spectroscope, a proprietary specially designed fibre-optic confocal Raman endoscopic probe that comprises a central light delivery fibre for laser light delivery and collection fibres for in vivo tissue Raman signal collection of tissue spectra and can be inserted into the instrument channel of conventional endoscopes and a proprietary control software that enables epithelial molecular information to be extracted and analyzed in real-time. Spectral information acquired by the system is matched against a database to quick diagnosis.
Endofotonics's top competitors include Scholar Rock, Ionpath and SamanTree Medical.
Endofotonics has 2 investors. Key investors include ZIG Ventures, and Seeds Capital.
Endofotonics operates through Endofotonics Pte Ltd.